Table 4 Treatment effects in patients with GC/GEJC/EAC, with negative/unknown HER2, on first-line treatment

Time since start of first-line treatment, days

629

158

139

123

88

35

86

 Mean (SD)

90 (163)

80 (93)

78 (86)

62 (43)

125 (370)

177 (193)

95 (69)

 Median (IQR)

62 (30–103)

51 (26–99)

62 (30–987)

49 (30–85)

58 (30–103)

166 (30–250)

81 (50–122)

Response to current therapy, n (%)

469

86

112

84

73

30

84

 Stable disease

166 (35.4)

32 (37.2)

41 (36.6)

25 (29.8)

25 (34.3)

16 (53.3)

27 (32.1)

 Partial response

273 (58.2)

49 (57.0)

67 (59.8)

59 (70.2)

38 (52.1)

10 (33.3)

50 (59.5)

 Complete response

8 (1.7)

2 (2.3)

0 (0.0)

0 (0.0)

4 (5.5)

0 (0.0)

2 (2.4)

 Disease progression

22 (4.7)

3 (3.5)

4 (3.6)

0 (0.0)

6 (8.2)

4 (13.3)

5 (6.0)

Nonpharmacological treatments, n (%)

682

168

146

145

99

36

88

 Surgery

162 (23.8)

19 (11.3)

65 (44.5)

11 (7.6)

17 (17.2)

7 (19.4)

43 (48.9)

 Radiotherapy

103 (15.1)

17 (10.1)

35 (24.0)

10 (6.9)

22 (22.2)

1 (2.8)

18 (20.5)

 Stent

72 (10.6)

16 (9.5)

12 (8.2)

30 (20.7)

10 (10.1)

3 (8.3)

1 (1.1)

 Laser therapy

5 (0.7)

0 (0.0)

4 (2.7)

0 (0.0)

1 (1.0)

0 (0.0)

0 (0.0)

 None

5 (0.7)

0 (0.0)

4 (2.7)

0 (0.0)

1 (1.0)

0 (0.0)

0 (0.0)

Bothered by side effects, n (%)

676

166

144

145

98

35

88

 Not at all

81 (12.0)

8 (4.8)

10 (6.9)

21 (14.5)

22 (22.5)

2 (5.7)

18 (20.5)

 A little bit

212 (31.4)

62 (37.4)

42 (29.2)

48 (33.1)

27 (27.6)

15 (42.9)

18 (20.5)

 Somewhat

247 (36.5)

51 (30.7)

67 (46.5)

55 (37.9)

25 (25.5)

14 (40.0)

35 (39.8)

 Quite a bit

110 (16.3)

42 (25.3)

19 (13.2)

14 (9.7)

19 (19.4)

3 (8.6)

13 (14.8)

 Very much

26 (3.9)

3 (1.8)

6 (4.2)

7 (4.8)

5 (5.1)

1 (2.9)

4 (4.6)